HIFU and Chemotherapy Trial in France for Prostate Cancer
Edap TMS SA (EDAP) said it is currently conducting clinical investigations in France under an approved clinical trial combining the company’s Ablatherm-HIFU device with chemotherapy using docetaxel.
The study is a primary treatment therapy program for men suffering from clinically localized but aggressive high risk prostate cancer typically classified as stage T2c. The study began in late 2006 and the company expects to enroll up to 30 men, of which more than 10 have already been treated. More details — press release.